⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer

Harshabad Singh Rachel B. Keller Kevin S. Kapner Julien Dilly Srivatsan Raghavan Chen Yuan Elizabeth F. Cohen Michael Tolstorukov Elizabeth Andrews Lauren K. Brais Annacarolina da Silva Kimberly Perez Douglas A. Rubinson Rishi Surana Marios Giannakis Kimmie Ng Thomas E. Clancy Matthew B. Yurgelun Benjamin L. Schlechter Jeffrey W. Clark Geoffrey I. Shapiro Michael H. Rosenthal Jason L. Hornick Valentina Nardi Yvonne Li Hersh Gupta Andrew D. Cherniack Matthew Meyerson James M. Cleary Jonathan A. Nowak Brian M. Wolpin Andrew J. Aguirre

View at Publisher

Ask AI

Bookmark

Share

Abstract

Copy number gains in MAPK genes are infrequent in KRAS WT, MAPK Negative pancreatic cancer

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Singh et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875227e1 https://doi.org/10.1158/1078-0432.27033427

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
2Supplementary Figure S6 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
3Supplementary Figure S6 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
4Supplementary Figure S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
5Supplementary Figure S5 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024

More related papers

Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
Supplementary Figure S8 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024